Cargando…
The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study
The COVID-19 pandemic caused unprecedented disruption in health service delivery, globally. This study sought to provide evidence on the impact of the pandemic on vaccine coverage in Kilifi County, Kenya. We conducted a vaccine coverage survey between April and June 2021 within the Kilifi Health and...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622384/ https://www.ncbi.nlm.nih.gov/pubmed/36543684 http://dx.doi.org/10.1016/j.vaccine.2022.10.074 |
_version_ | 1784821755734392832 |
---|---|
author | Lucinde, R.K. Karia, B. Ouma, N. Amadi, D. Nyundo, C. Mataza, C. Nyaguara, A. Scott, J.A.G. Gallagher, K.E. Kagucia, E. |
author_facet | Lucinde, R.K. Karia, B. Ouma, N. Amadi, D. Nyundo, C. Mataza, C. Nyaguara, A. Scott, J.A.G. Gallagher, K.E. Kagucia, E. |
author_sort | Lucinde, R.K. |
collection | PubMed |
description | The COVID-19 pandemic caused unprecedented disruption in health service delivery, globally. This study sought to provide evidence on the impact of the pandemic on vaccine coverage in Kilifi County, Kenya. We conducted a vaccine coverage survey between April and June 2021 within the Kilifi Health and Demographic Surveillance System (KHDSS). Simple random sampling was used to identify 1500 children aged 6 weeks–59 months. Participants were grouped into three retrospective cohorts based on when they became age-eligible for vaccination: before the pandemic, during the first year, or during the second year of the pandemic. Survival analysis with Cox regression was used to evaluate the association between the time-period at which participants became age-eligible for vaccination and the rate of vaccination within a month of age-eligibility for the third dose of pentavalent vaccine (Pentavalent-3) and within three months of age-eligibility for the first dose of Measles vaccine (MCV-1). A total of 1,341 participants were included in the survey. Compared to the pre-COVID-19 baseline period, the rate of vaccination within a month of age-eligibility for Pentavalent-3 was not significantly different in the first year of the pandemic (adjusted hazard ratio [aHR] 1.03, 95 % confidence interval [CI] 0.90–1.18) and was significantly higher during the second year of the pandemic (aHR 1.33, 95 % CI 1.07–1.65). The rate of vaccination with MCV-1 within three months of age-eligibility was not significantly different among those age-eligible for vaccination during the first year of the pandemic (aHR 1.04, 95 % CI 0.88–1.21) and was 35 % higher during the second year of the pandemic (95 % CI 1.11–1.64), compared to those age-eligible pre-COVID-19. After adjusting for known determinants of vaccination, the COVID-19 pandemic did not adversely affect the rate of vaccination within the KHDSS. |
format | Online Article Text |
id | pubmed-9622384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Authors. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96223842022-11-01 The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study Lucinde, R.K. Karia, B. Ouma, N. Amadi, D. Nyundo, C. Mataza, C. Nyaguara, A. Scott, J.A.G. Gallagher, K.E. Kagucia, E. Vaccine Article The COVID-19 pandemic caused unprecedented disruption in health service delivery, globally. This study sought to provide evidence on the impact of the pandemic on vaccine coverage in Kilifi County, Kenya. We conducted a vaccine coverage survey between April and June 2021 within the Kilifi Health and Demographic Surveillance System (KHDSS). Simple random sampling was used to identify 1500 children aged 6 weeks–59 months. Participants were grouped into three retrospective cohorts based on when they became age-eligible for vaccination: before the pandemic, during the first year, or during the second year of the pandemic. Survival analysis with Cox regression was used to evaluate the association between the time-period at which participants became age-eligible for vaccination and the rate of vaccination within a month of age-eligibility for the third dose of pentavalent vaccine (Pentavalent-3) and within three months of age-eligibility for the first dose of Measles vaccine (MCV-1). A total of 1,341 participants were included in the survey. Compared to the pre-COVID-19 baseline period, the rate of vaccination within a month of age-eligibility for Pentavalent-3 was not significantly different in the first year of the pandemic (adjusted hazard ratio [aHR] 1.03, 95 % confidence interval [CI] 0.90–1.18) and was significantly higher during the second year of the pandemic (aHR 1.33, 95 % CI 1.07–1.65). The rate of vaccination with MCV-1 within three months of age-eligibility was not significantly different among those age-eligible for vaccination during the first year of the pandemic (aHR 1.04, 95 % CI 0.88–1.21) and was 35 % higher during the second year of the pandemic (95 % CI 1.11–1.64), compared to those age-eligible pre-COVID-19. After adjusting for known determinants of vaccination, the COVID-19 pandemic did not adversely affect the rate of vaccination within the KHDSS. The Authors. Published by Elsevier Ltd. 2023-01-16 2022-11-01 /pmc/articles/PMC9622384/ /pubmed/36543684 http://dx.doi.org/10.1016/j.vaccine.2022.10.074 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Lucinde, R.K. Karia, B. Ouma, N. Amadi, D. Nyundo, C. Mataza, C. Nyaguara, A. Scott, J.A.G. Gallagher, K.E. Kagucia, E. The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study |
title | The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study |
title_full | The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study |
title_fullStr | The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study |
title_full_unstemmed | The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study |
title_short | The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study |
title_sort | impact of the covid-19 pandemic on vaccine coverage in kilifi, kenya: a retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622384/ https://www.ncbi.nlm.nih.gov/pubmed/36543684 http://dx.doi.org/10.1016/j.vaccine.2022.10.074 |
work_keys_str_mv | AT lucinderk theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT kariab theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT ouman theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT amadid theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT nyundoc theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT matazac theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT nyaguaraa theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT scottjag theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT gallagherke theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT kaguciae theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT lucinderk impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT kariab impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT ouman impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT amadid impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT nyundoc impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT matazac impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT nyaguaraa impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT scottjag impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT gallagherke impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy AT kaguciae impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy |